Advantages and limitations of platinib (Pujihua) in clinical application in China

Pralsetinib is a selective RETkinase inhibitor, mainly used for RET fusion-positive non-small cell lung cancer (NSCLC) and certain RET mutation-related thyroid cancers. In clinical application in China, the biggest advantage of platinib is its high targeting and significant efficacy against RET-driven tumors. Compared with traditional chemotherapy, its objective response rate and disease control rate are significantly improved, and it can quickly improve patients' symptoms and improve their quality of life.

In addition, platinib is convenient to take orally, and patients can complete treatment at home, reducing the number of hospitalizations. Compared with early multi-target RET inhibitors, platinib is more selective and has a more controllable side effect spectrum. It mainly manifests as hematological toxicity and mild liver function abnormalities. Most patients can continue treatment through dose adjustment or symptomatic treatment, thereby achieving long-term maintenance of efficacy.

However, platinib also has limitations in clinical application. First of all, its price is relatively high and has not yet been fully covered by medical insurance, which brings a certain financial burden to patients. Secondly, some patients may develop drug resistance or disease progression, especially after previous treatment with other targeted drugs, and the efficacy of a single drug may be limited. Furthermore, patients with severe hepatic and renal dysfunction or cardiovascular disease need to be used with caution and closely monitored.

Overall, platinib has the advantages of precise targeting, significant efficacy and oral convenience in clinical applications in China, and is an important treatment option for patients with RET driven tumors. However, the high cost, risk of drug resistance and restrictions on use in some special groups still require clinical attention. In the future, through the expansion of medical insurance coverage and the exploration of combination therapies, it is expected to further improve its clinical accessibility and therapeutic effects.

Reference materials:https://www.drugs.com/